Sanofi/€SAN
1D1W1MYTD1Y5YMAX
Capital at risk
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Ticker
- €SAN
- Sector
- Health
- Primary listing
- PAR
- Employees
- 74,846
- Headquarters
- Paris, France
- Website
- www.sanofi.com
Sanofi Metrics
BasicAdvanced
€89B
22.90
€3.26
-
€4.12
5.51%
Price and volume
Market cap
€89B
52-week high
€90.90
52-week low
€71.25
Average daily volume
1.8M
Dividend rate
€4.12
Financial strength
Current ratio
0.987
Quick ratio
0.487
Long term debt to equity
23.464
Total debt to equity
33.89
Dividend payout ratio (TTM)
124.38%
Interest coverage (TTM)
17.08%
Profitability
EBITDA (TTM)
13,657
Gross margin (TTM)
73.45%
Net profit margin (TTM)
8.09%
Operating margin (TTM)
21.16%
Effective tax rate (TTM)
23.16%
Revenue per employee (TTM)
€650,000
Management effectiveness
Return on assets (TTM)
5.07%
Return on equity (TTM)
5.71%
Valuation
Price to earnings (TTM)
22.899
Price to revenue (TTM)
1.845
Price to book
1.29
Price to tangible book (TTM)
99.98
Price to free cash flow (TTM)
10.716
Free cash flow yield (TTM)
9.33%
Free cash flow per share (TTM)
6.974
Dividend yield (TTM)
5.51%
Forward dividend yield
5.51%
Growth
Revenue change (TTM)
6.95%
Earnings per share change (TTM)
-55.56%
3-year revenue growth (CAGR)
2.04%
10-year revenue growth (CAGR)
3.67%
3-year earnings per share growth (CAGR)
-21.90%
10-year earnings per share growth (CAGR)
0.16%
3-year dividend per share growth (CAGR)
4.99%
10-year dividend per share growth (CAGR)
3.47%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Analyst projections of the future price of Sanofi stock.
Bulls say / Bears say
The EMA’s human medicines committee recommended approval for tolebrutinib (Cenrifki) to treat progressive MS in April 2026, bolstering Sanofi’s European pipeline after the US setback (Bloomberg).
Sanofi reported that its experimental IBD drug duvakitug, developed with Teva, maintained benefits over 44 weeks in UC and Crohn’s patients, marking a strong phase II readout that diversifies its immunology portfolio (Bloomberg).
On July 30, 2026, Sanofi raised its full-year 2026 sales growth outlook to ~10% at constant exchange rates, up from high-single digits, driven by robust Dupixent demand (Reuters).
Shares fell 8% on July 30, 2026, as investors focused on pipeline cuts and one-off gains despite Sanofi lifting its sales forecast, highlighting skepticism about the sustainability of its growth trajectory (Reuters).
Sanofi’s multiple sclerosis drug tolebrutinib was rejected by the FDA late in 2025 due to safety concerns, constraining its expansion in the U.S. MS market and limiting diversification of its portfolio (Bloomberg).
Chief Executive Paul Hudson was abruptly replaced in February 2026 after increased R&D spending failed to yield rapid pipeline results, underscoring challenges in rejuvenating Sanofi’s late-stage drug development engine (Bloomberg).
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Sanofi
AllEURGBPUSD
Fund name | Fund size | €SAN weighting |
|---|---|---|
Amundi CAC 40€C40 | €999M | 6.03% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 5.22% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 5.22% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 5.17% |
iShares Edge MSCI Europe Value Factor£IEFV | £2.2B | 4.31% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.